Hongming Chen, Executive Vice President of research
Kala Pharmaceuticals, Boston, MA, USA
Hongming Chen, Sc.D. is currently the Executive Vice President of Research at Kala Pharmaceuticals. Dr. Chen helped to start Kala in 2009 and is responsible for all R&D activities.
Prior to joining Kala, Dr. Chen was at TransForm Pharmaceuticals, where she was Director of Formulation Development and was responsible for formulation and design for drugs and device combinations. Dr. Chen was one of the founders of TransForm. She helped build the company from the beginning until its acquisition by Johnson & Johnson in 2005 for $230 million. During her time there Dr. Chen also conducted vaccine and drug delivery research and development at AstraZeneca and at Merck. In conjunction with her research on drug delivery Dr. Chen will be a Plenary speakers at MIT’s 13th US-Japan Symposium on Drug Delivery. She will be presenting a lecture on the Development of Mucus Penetrating Particles for Treating Ocular Diseases.
Mass High Tech named Dr. Chen as one of its Women to Watch for 2014, an annual program recognizing female leaders who are shaping the future and the sciences. In 2015, Dr. Chen was elected to the College of Fellows at the American Institute for Medical and Biological Engineering.
She has a B.S. in Chemical Engineering and a Masters and Sc.D. in Chemical Engineering from The University of Texas at Austin and Massachusetts Institute of Technology respectively.